Format

Send to

Choose Destination
Cancer Lett. 2015 Jan 28;356(2 Pt B):347-56. doi: 10.1016/j.canlet.2014.10.045. Epub 2014 Nov 10.

Adeno-associated virus-mediated cancer gene therapy: current status.

Author information

1
Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Qingchun Road NO.3, Hangzhou, Zhejiang, China.
2
Department of Nephrology, Zhuji People's Hospital, Zhuji, Zhejiang, China.
3
Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Qingchun Road NO.3, Hangzhou, Zhejiang, China; Image-Guided Bio-Molecular Intervention Research, Department of Radiology, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: xmyang@uw.edu.

Abstract

Gene therapy is one of the frontiers of modern medicine. Adeno-associated virus (AAV)-mediated gene therapy is becoming a promising approach to treat a variety of diseases and cancers. AAV-mediated cancer gene therapies have rapidly advanced due to their superiority to other gene-carrying vectors, such as the lack of pathogenicity, the ability to transfect both dividing and non-dividing cells, low host immune response, and long-term expression. This article reviews and provides up to date knowledge on AAV-mediated cancer gene therapy.

KEYWORDS:

Adeno-associated virus; Cancer; Cancer gene therapy; Gene vehicle

PMID:
25444906
PMCID:
PMC4259838
DOI:
10.1016/j.canlet.2014.10.045
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center